Evidence map›Paper›PMID 40507882›Full record

ArticleInternational journal of molecular sciences2025

Evaluating Glial Fibrillary Acidic Protein and Neurofilament Light as Potential Biomarkers for Spinocerebellar Ataxia 7.

Rana Hanna Al-Shaikh, Karen Jansen-West, Audrey Strongosky, Zoe Parrales, Judith A Dunmore, Yuping Song, Tania F Gendron, Juan C Guevara, Helio A G Teive, Jarosław Dulski and 4 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rana Hanna Al-ShaikhDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-0447-4089
Karen Jansen-WestDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Audrey StrongoskyDepartment of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
Zoe ParralesDepartment of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
Judith A DunmoreDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-0190-0089
Yuping SongDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Tania F GendronDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Juan C GuevaraDepartment of Science, University of Barcelona, 08007 Barcelona, Spain.
Helio A G TeiveMovement Disorders Unit, Neurology Service, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba 80060-90, PR, Brazil.ORCID 0000-0003-2305-1073
Jarosław DulskiDepartment of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
Jarosław SławekDivision of Neurological and Psychiatric Nursing, Medical University of Gdańsk, 80-211 Gdansk, Poland.
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0001-5487-1053
Mercedes PrudencioDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-4894-4858

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI DANIEL H GESCHWIND · 2019 to 2026
$120.9M
Expanding insights into FTD disease mechanismsR35NS097273 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2017 to 2024
$10.6M
Human Biomarkers CoreU54NS123743 · NINDS · STANFORD UNIVERSITY · PI FRATTA, PIETRO, GITLER, AARON D. · 2021 to 2025
$8.2M
Stathmin-2 and TDP-43 neurodegeneration in Alzheimer’s and multi-etiology dementiasR01NS120992 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, PRUDENCIO, MERCEDES · 2024 to 2025
$1.6M
NIA NIH HHS U19 AG063911NINDS NIH HHS R01 NS120992NINDS NIH HHS R35 NS097273NINDS NIH HHS U54 NS123743
6 · The paper itself

Abstract

Spinocerebellar ataxia type 7 (SCA7), a rare form of ataxia, possesses a wide phenotypic spectrum ranging from classic ataxic symptoms to blindness, multiorgan failure, cardiomyopathy, and early death among younger age groups. Biomarkers associated with disease progression and severity could aid in disease prognostication. We evaluated the utility of glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) in distinguishing patients with SCA7 from healthy controls and estimating patient prognosis. GFAP and NfL levels were measured in 23 plasma and 20 cerebrospinal fluid (CSF) samples from asymptomatic (N = 3) and symptomatic SCA7 participants (N = 10) and from healthy controls (N = 8). GFAP concentrations were elevated in the plasma (82.7 pg/mL) and CSF (9318 pg/mL) of patients with SCA7 compared to controls (plasma: 48.0 pg/mL; CSF: 89,056 pg/mL). Similarly, NfL plasma (21.6 pg/mL) and CSF (2615.0 pg/mL) levels were also significantly upregulated in SCA7 compared to controls (plasma: 8.2 pg/mL; CSF: 414.6 pg/mL). Higher levels of NfL, but not of GFAP, significantly discriminated symptomatic SCA7 patients from controls (area under de curve, AUC: 0.898,

Indexed as

Glial Fibrillary Acidic ProteinNeurofilament ProteinsSpinocerebellar AtaxiasAdultAgedBiomarkersCase-Control StudiesDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament ProteinsataxiabiomarkerGFAPNfL

Identifiers

PMID40507882
PMCPMC12154444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.